KRAS G12V clinical trials at UCSF

1 research study open to eligible people

Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
open to eligible people ages 18 years and up
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study…
San Francisco, California and other locations

Our lead scientists for KRAS G12V research studies include Bridget Keenan.

Last updated: February 24, 2025

Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor